Kornimate/medical-research-clean huggingface dataset:
effectiveness of bp remote monitoring with virtual physician management in hypertensive patients.

Conditions: Hypertension; Stroke (CVA) or TIA

Summary: to assess the feasibility and adoptability of dailydoctor's remote monitoring clinical decision support software tool in helping physicians virtually manage systolic blood pressures among patients with history of stroke or tia to a target systolic blood pressure (\<140 mmhg or a lower target range specified by referring physicians) using remote monitoring and independent clinical judgement.

to assess the feasibility and adoptability of dailydoctor's remote monitoring clinical decision support software tool in helping physicians virtually manage systolic blood pressures among patients with history of stroke or tia to a target systolic blood pressure (\<140 mmhg or a lower target range specified by referring physicians) using remote monitoring and independent clinical judgement. to assess the feasibility and adoptability of dailydoctor's digital platform in helping stanford stroke center lower and maintain systolic blood pressures among patients with history of stroke or tia to a target systolic blood pressure (\<140 mmhg or a lower target range specified by referring physicians) using remote monitoring and a virtual medical team focused on bp management.

Eligibility criteria:
inclusion criteria: age 18 years or older. a history of ischemic or hemorrhagic stroke, or transient ischemic attack. the ability to report blood pressure values by phone (either a patient or designated caregiver may call to report values). at least 2 bp measurements that are ≥140 mmhg systolic or ≥90 mmhg diastolic obtained on different days in the last 6 months in any setting (including at home, in clinic, or in the hospital setting). the referring physician feels the patient would benefit from bp optimization. consent to receive care from telehealth physicians available through the dailydoctor monitoring platform. english or spanish speaking. exclusion criteria: currently enrolled in another interventional research study inability to comply with study protocol have a planned surgical procedure during the study period upper arm circumference \> 20 inches has diagnosis of end-stage renal disease (gfr \ 2.0 mg/dl (176.8 μmol/l), or currently undergoing dialysis treatment (10) women who are pregnant or who are planning to become pregnant during the study period. blood pressure reduction is not indicated (e.g. patients who have a high blood pressure target to augment cerebral perfusion). any other reason that, in the opinion of the investigator, makes the person a poor candidate for participation in this study

Keywords: remote patient monitoring digital health monitoring blood pressure monitoring
ambulatory rehabilitation program in patients with degenerative rupture of the rotator cuff tendons of the shoulder

Conditions: Shoulder Pain

Summary: the main objective of the research is to study the effectiveness of an ambulatory rehabilitation program based on mobilization and muscular solicitation, during painful shoulders by full-thickness degenerative rupture of the tendons of the rotator cuff. , with the algo-functional state, ie pain and activity limitation, as judgment criteria, at 3 months.

our hypothesis is that rehabilitation based on mobilization and muscular solicitation is effective in painful shoulder due to degenerative rupture of the tendons of the rotator cuff; that it reduces pain, functional limitation and the need for surgery. research excluding health products: experimental group: ambulatory rehabilitation program based on mobilization and muscular solicitation control group: ambulatory rehabilitation program using of ultrasound physiotherapy

Eligibility criteria:
inclusion criteria: 1. age ≥ 55 years old, 2. painful shoulder for at least 1 month, 3. shoulder treated with at least one cortisone infiltration one month or more before inclusion, 4. pain ≥ 40/100 on visual analog scale, 5. pain reproduced by at least one clinical test of rotator cuff tendons or subacromial impingement (jobe, patte, neer, yocum test, hawkins), 6. full-thickness tear of at least one tendon of the rotator cuff attested by imaging, 7. affiliation to social security exclusion criteria: 1. passive glenohumeral mobility of the shoulder limited, 2. calcifying tendinopathy on standard radiography, 3. glenohumeral arthropathy; 4. painful acromioclavicular arthropathy; 5. history of shoulder fracture; 6. neurogenic pain or neurogenic motor deficit of the upper limb; 7. cortisone infiltration of the shoulder in the month preceding inclusion; 8. operated shoulder; 9. systemic pathologies including inflammatory rheumatism or neoplastic pathology; 10. patient participating in another experimental research; 11. patient under legal protection (curators or guardianship) 12. patient deprived of liberty by a judicial or administrative decision 13. pregnant or breastfeeding woman

Keywords: shoulder pain rotator cuff tendons ambulatory rehabilitation
national cooperative growth study (ncgs) of optimal nutropin aq and nutropin dosing in pubertal growth hormone-deficient (ghd) patients

Conditions: Dwarfism, Pituitary

Summary: this study is a multicenter, open-label, observational, postmarketing surveillance study that will collect information on the use of genentech gh preparations to treat gh-deficient subjects with optimal gh dosing during puberty.


Eligibility criteria:
inclusion criteria: * adolescent boys who are gh deficient and tanner stage 2 or greater (testes 3 ml or greater) * adolescent girls who are gh deficient and breast tanner stage 2 or greater * current treatment with gh dose of 0.4 to 0.7 mg/kg/wk * ability to keep follow-up appointments throughout the study * willingness to remain on therapy until epiphyseal closure is achieved * prior enrollment in ncgs core study 85-036 exclusion criteria: * treatment with non-genentech gh preparation * closed epiphyses * active neoplasia * treatment with insulin for diabetes

Keywords: pubertal growth hormone deficiency
effects of whole-body vibration exercise in brain injury patients with minimally conscious state

Conditions: Brain Injuries; Minimally Conscious State

Summary: the purpose of this study is to investigate the effect of the whole body vibration exercise on cortical activity and consciousness level in brain injury patients with minimally conscious state.

whole body vibration exercise can provide proper somatosensory stimulation and improve muscle strength and postural control. however, there has not yet been a report on the cortical activity changes induced by whole body vibration exercise in brain injury patients with minimally conscious state. patients will be randomly assigned to one of the two groups. one group will go through whole body vibration with exercise and the other will only perform exercise. the primary outcome measurement of this study was cerebral cortex activity based on changes in oxygenated hemoglobin concentration using functional near-infrared spectroscopy. behavioral assessment were performed using the coma recovery scale-revised and modified ashworth scale.

Eligibility criteria:
inclusion criteria: * patients whose consciousness level was assessed as minimally conscious state by traumatic brain injury, stroke, and hypoxic brain injury * patients who had more than 3 months after brain injury exclusion criteria: * patients under 18 years of age and older patients over 80 years * pregnant women * in cases of uncontrolled internal or external disease * patients with severe heart, musculoskeletal problems and disabilities, and those with severe neurological lesions prior to brain injury * acute or chronic venous thrombosis or hemorrhage * person wearing an implant on the spine * people with severe osteoporosis
auricular acupressure : improves oxaliplatin-induced peripheral neuropathy

Conditions: Oxaliplatin-induced Peripheral Neuropathy; Chemotherapy

Summary: oxaliplatin-induced peripheral neuropathy (oipn) is a common adverse effect that becomes worse as the drug dose accumulation impacts cancer patients' daily activities and quality of life.the result of this study will determine the immediate effects of the 8-week auricular acupuncture intervention on alleviating the participants' oipn symptoms and enhancing their quality of life. this study will continue to evaluate the carry-over effects of auricular acupuncture after the chemotherapy course ends.

objectives: oxaliplatin-induced peripheral neuropathy (oipn) is a common adverse effect that becomes worse as the drug dose accumulation impacts cancer patients' daily activities and quality of life. this study aims to evaluate the immediate and carry-over effects of auricular acupressure on oipn symptoms and quality of life for colorectal cancer patients. methods : this randomized trial will recruit 76 participants with colorectal cancer and oipn from the oncology outpatient department in taiwan. the control group will receive usual care, whereas the experimental group will receive usual care in addition to auricular acupressure for 8 weeks. outcomes will be assessed by using the chemotherapy-induced peripheral neuropathy assessment tool, neuropathic pain symptom inventory, pain visual analogue scale, and the european organization for research and treatment of cancer-quality of life questionnaire-core 30. these assessment tools are used before the intervention, biweekly during the intervention, 2 weeks after the intervention, and one month after the end of the chemotherapy course. hypothesis: ultimately, the result of this study will determine the immediate effects of the 8-week auricular acupuncture intervention on alleviating the participants' oipn symptoms and enhancing their quality of life. this study will continue to evaluate the carry-over effects of auricular acupuncture after the chemotherapy course ends.

Eligibility criteria:
inclusion criteria: * colorectal cancer patients who are above the age of 20 years * have experiencing oxaliplatin induced peripheral neuropathy * must be able to communicate * willing to fill out the inform consent exclusion criteria: * symptoms of peripheral neuropathy caused by diabetes mellitus * symptoms of peripheral neuropathy caused by genetic disease * symptoms of peripheral neuropathy caused by spinal cord injury * symptoms of peripheral neuropathy caused by alcoholism * with wounds on ears * allergy to latex (the tapes for the auricular acupressure include latex)

Keywords: colorectal cancer chemotherapy oxaliplatin-induced peripheral neuropathy auricular acupressure pain quality of life
clinical trial assessing the efficacy of capsaicin patch (qutenza®) in cancer patients with neuropathic pain

Conditions: Neuropathic Pain

Summary: in the oncology area, neuropathic pains are relatively frequent and can be induced by surgery, radiotherapy, or chemotherapy. in usual practice, some units are using qutenza in order to reduce neuropathic pain even though using of this patch for a population of cancer patients has never been demonstrated so far in a prospective study. the present prospective study proposes to evaluate the qutenza efficacy in peripheric neuropathic pain in cancer patients.

drugs for neuropathic pains are generally represented by antidepressants, anti-epileptics, opioids, lidocaine patch. however, these drugs can frequently be insufficient, and/or can lead to side effects. qutenza (8% capsaicin patch) presents an interesting alternative. qutenza efficacy has been shown in five principal studies conducted on 1988 adults affected by moderate or severe neuropathic pains. all patients presented postherpetic neuralgia, or hiv associated therapy, or painful diabetic peripheric neuropathies. these studies led to qutenza approbation in europe and in states in 2009. in oncology, neuropathic pains are relatively frequent and can be induced by the three big actors of the anti-cancerous therapeutic arsenal (surgery, radiotherapy, chemotherapy). in usual practice, some units are usually using qutenza, but the use of this patch for this kind of patients has not been shown in a prospective study. advantages of this treatment are numerous, and results presented in other therapeutic area are encouraging its use in oncology. the present prospective study proposes to evaluate the qutenza efficacy in peripheric neuropathic pain in cancer patients.

Eligibility criteria:
inclusion criteria: * patient with at least 18 years old; * patient presenting neuropathic pain secondary to an anti-cancerous treatment; * patient presenting a dn4 (neuropathic pain in four questions) score superior or equal to 4 out of 10 * patient presenting a skin without lesion at the painful area * informed consent form signed; * patient affiliated to a social security scheme. exclusion criteria: * hypersensitivity known to capsaicin; * instable or uncontrolled hypertension; * painful area localised next to eyes; * pregnant or breastfeeding woman; * protected people.

Keywords: neuropathic pain qutenza capsaicin cancer patient
sit to stand intervention for allina health employees

Conditions: Stress; Quality of Life

Summary: a 16 week pilot study for allina call center employees to look at the psychological outcomes and biological markers after an intervention of using a standing work station. there were two groups: group 1 received, and was instructed to use, the standing work station for all 16 weeks, group 2 was a wait-list control group and received, and was instructed to use, the standing work station for the second 8 weeks. psychological outcomes were measured at weeks 0, 4, 8, 12, and 16. biological markers were measured at weeks 0, 8, and 16.


Eligibility criteria:
inclusion criteria: * allina health call center employee (75% or higher employee status) * aged 18 to 65 years * provide written informed consent exclusion criteria: * unable to stand for 20 minutes continuously unaided * home based employees

Keywords: standing workstation
efficacy and safety of avatrombopag for treating tcp in hbv-aclf patients receiving alss treatment

Conditions: Thrombocytopenia; Hepatitis B, Chronic; Acute-On-Chronic Liver Failure

Summary: this study aims to investigate the efficacy and safety of avatrombopag for treating thrombocytopenia in hepatitis b virus related acute-on-chronic liver failure patients receiving artificial liver support system treatment.

artificial liver support system (alss) is an optimal therapy in patients with hepatitis b virus (hbv) related acute-on-chronic liver failure (aclf). but a lot of patients encount thrombocytopenia (tcp) due to the mechanical damage of thrombocyte and use of heparin during the treatment. avatrombopag is an oral thrombopoietin receptor agonist that has been recently approved for treating tcp in chronic liver disease patients needing invasive procedures. therefore, this study aims to investigate the efficacy and safety of avatrombopag for treating tcp in hbv related aclf patients receiving alss treatment. sixty patients with hbv related aclf receiving alss will be enrolled in this study. the participants are divided into trial group (avatrombopag, double plasma molecular adsorption system (dpmas) , low volume plasma exchange (lpe), and comprehensive internal medical treatment) and control group (dpmas, lpe, comprehensive internal medical treatment). symptoms, signs, laboratory tests results, adverse events, mortality rates are recorded from treatment baseline to 3 weeks.

Eligibility criteria:
inclusion criteria: 1. age from 18 to 65 years old; 2. clinical diagnosis of chronic hepatitis b virus infection (positive hepatitis b surface antigen or positive hepatitis b virus dna \> 0.5 year); 3. clinical diagnosis of liver failure (serum total bilirubin level \> 10 times upper limit of normal; prothrombin time activity \ 1.5); 4. platelets \ 50\*10 e9/l. 5. signed informed consent form. exclusion criteria: 1. other active liver diseases; 2. hepatocellular carcinoma or other malignancy; 3. pregnancy or lactation; 4. human immunodeficiency virus infection or congenital immune deficiency diseases; 5. severe diabetes, autoimmune diseases; unstable infarction due to cardio-cerebrovascular events; other important organ dysfunctions or transplantation; 6. severe complications including severe infection, gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome; 7. patients with alss treatment in one week; 8. thrombotic disease; 9. patients can not follow-up; 10. investigator considering inappropriate.

Keywords: thrombocytopenia hepatitis b virus acute-on-chronic liver failure double plasma molecular adsorption system plasma exchange artificial liver support system
study in urology practices looking at impact of oncotypedx gps test on men choosing and remaining on active surveillance

Conditions: Prostate Cancer

Summary: genomic health's oncotypedx® prostate cancer assay is a commercially available laboratory test that measures the activity of certain genes in prostate cancer. the purpose of this study is to better understand how the use of this test result impacts or affects treatment decisions for men newly diagnosed with low risk prostate cancer, their confidence in the treatment decision, and the effects and side effects of the treatment chosen on certain aspects of quality of life. this study will also determine what percentage of men choosing an active monitoring program as prescribed by their doctor remain on active surveillance and have avoided any treatment at one year after diagnosis after receiving the assay result.

this is a multicenter observational study that evaluates eligible patients who will submit prostate cancer diagnostic biopsy tissues for oncotype dx prostate cancer assay testing. a physician treatment recommendation will be made and the assay is ordered. the physician will review clinical data, the gps report and discuss treatment options with the patient. at the following visit, a shared physician-patient treatment decision (immediate treatment or as) will be made. men selecting as as primary treatment will be followed to assess persistence on as. there is no required or standardized as protocol for this study and the intensity of surveillance will be at the discretion of the investigator. patients will not be required, but may undergo a standard trus guided surveillance biopsy at one year. in this study, the oncotype dx prostate cancer assay will be assessed on the diagnostic biopsy only and will not be assessed on subsequent biopsies.

Eligibility criteria:
inclusion criteria: * clinical stage t1c/t2 * psa ≤ 20ng/ml * biopsy gs ≤ 6 with any number of cores positive, or biopsy gs 3+4 disease with ≤3 positive cores or ≤ 33% positive cores * the patient must be ≥ 50 years of age * the patient must have a life expectancy of \> 10 years * patient must be able to give consent in english or spanish exclusion criteria: * clinical stage t3a or above * psa \> 20ng/ml * biopsy gs 4+3 or \> 8 * known metastatic prostate cancer * positive biopsy for prostate cancer \> 3 months ago * treatment decision has already been made * insufficient tumor in prostate biopsy tissue to perform the assay * treatment with androgen deprivation therapy (adt) prior to prostate biopsy * diagnosis made by transurethral resection of prostate (turp) shavings * any psychiatric or psychological conditions * contraindications to primary treatment according to physician's judgment

Keywords: prostate cancer localized prostate cancer low risk prostate cancer active surveillance active monitoring oncotypedx gps genomic prostate score genomic test molecular test
persistency study after ap / tdap booster vaccines in adult subjects (v113_01 extension 1)

Conditions: Pertussis

Summary: the purpose of this study is to evaluate the persistence of immune response against the three pertussis antigens (anti- pertussis toxoid (pt), anti-filamentous hemagglutinin (fha) and anti-pertactin (prn)) in subjects who received a booster dose of either ap or tdap study vaccines or boostrix® during v113_01 study. there was only one clinic visit at day 1. eligible subjects went undergo a single blood draw after which they were observed for approximately 15 minutes. approximately 10.0 ml of blood was withdrawn. no vaccine was administered and no safety data was collected in this study.


Eligibility criteria:
inclusion criteria: * healthy individuals previously enrolled in v113_01 trial, who completed the study following study protocol and who received the appropriate booster vaccine per group assignment * individuals who voluntarily gave written informed consent after the nature of the study was explained according to local regulatory requirements, prior to study entry * individuals who could comply with study procedures including follow-up exclusion criteria: 1. clinical conditions representing a contraindication to blood draw. 2. abnormal function of the immune system resulting from: * clinical conditions * systemic administration of corticosteroids per oral (po)/ intravenous (iv)/ intramuscular (im) for more than 14 consecutive days within 90 days prior to informed consent. * administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to informed consent. 3. received immunoglobulins or any blood products within 180 days prior to informed consent. 4. received an investigational or non-registered medicinal product within 30 days prior to informed consent 5. study personnel as an immediate family or household member 6. any other clinical condition that, in the opinion of the investigator, could interfere with the results of the study or pose additional risk to the subject due to participation in the study
efficacy and safety study of uracyst to treat interstitial cystitis/painful bladder syndrome

Conditions: Interstitial Cystitis; Painful Bladder Syndrome

Summary: a new device for interstitial cystitis is compared to inactive control to determine if it is safe and effective. the study lasts approximately 7 weeks with a 19-week follow-up period.

multi-center, randomized, double-blind, parallel, 8 weekly instillations over a 7-week period with post-treatment follow-up for an additional 19 weeks for a total study length of 26 weeks.

Eligibility criteria:
inclusion criteria: * are a female, 18 years or older * have been diagnosed with ic/pbs * are willing to provide written informed consent and authorization to disclose after being fully informed of the risks of participation exclusion criteria: * are lactating females * have previously received investigational products or devices within 30 days of screening * have previously received uracyst * are currently receiving therapy with interstim® * have any other condition/disease which, in the opinion of the investigator, could compromise subject safety or confound the interpretation of study results * are unable or unwilling to comply with protocol requirements

Keywords: bladder pain gag replacement therapy ic/pbs